Latest News Archive

Please select Category, Year, and then Month to display items
Previous Archive
10 December 2018 | Story Leonie Bolleurs | Photo Leonie Bolleurs
One step closer to treat HIV/Aids
Nthabiseng Mokoena is working on an article based on her research about drug development in infection models, which will be published under the Research Chair in Pathogenic Yeasts.

South Africa has the biggest and most high-profile HIV epidemic in the world, with an estimated seven million people living with HIV in 2015. In the same year, there were 380 000 new infections while 180 000 South Africans died from AIDS-related illnesses. 

Invasive fungal infection, common in certain groups of patients with immune deficits, is a serious driver of global mortality in the context of the global HIV pandemic. 

“Despite a major scientific effort to find new cures and vaccines for HIV, hundreds of thousands of HIV-infected individuals continue to die on a yearly basis from secondary fungal infection. Intensive research needs to be done to help reduce the unacceptably high mortality rate due to the infection in South Africa,” said Nthabiseng Mokoena.

Mokoena is a master’s student of Prof Carlien Pohl-Albertyn, who is heading the Research Chair in Pathogenic Yeasts in the Department of Microbial, Biochemical and Food Biotechnology at the University of the Free State (UFS). 

She received her master’s degree at the December graduations of the UFS. Her thesis is titled: Caenorhabditis elegans as a model for Candida albicans-Pseudomonas aeruginosa co-infection and infection induced prostaglandin production.

Research Chair in Pathogenic Yeasts

Earlier this year, the National Research Foundation approved the Research Chair in Pathogenic Yeasts. One of the projects of the group of scientists in this chair include a study of the interaction between the yeast, Candida albicans and the bacterium, Pseudomonas aeruginosa in different hosts, using a variety of infection models.

In her research, Mokoena studied the response of infectious pathogens such as yeasts and bacteria, using a nematode (little roundworm) as an infection model to mimic the host environment. Nematodes have a number of traits similar to humans. It is thus a good alternative for humans as infection models, as it is unethical to use the latter.

Nematodes have a number of advantages, including its low cost and fast reproduction and growth. 

Mokoena monitored the survival of the nematodes to see how infectious the pathogens are, especially in combination with each other. 

Role of infection model for drug development

When these two pathogens were studied in a lab (in vitro), it was found that they can inhibit each other, but after studying them in the infection model (in vivo), Mokoena showed that these pathogens are more destructive together. 

This finding has a huge impact for the pharmaceutical industry, as it can provide information on how drugs need to be designed in order to fight infectious diseases where multiple organisms cause co-infections.

Many pathogens are resistant to drugs. Through this model, drugs can be tested in a space similar to the human body. Seeing how pathogens react to drugs within a space similar to the human body, can contribute to drug development. 

Not only are drugs developed more effectively through this model, it is also less expensive. 

It is the first time that the combination of the yeast, Candida albicans and the bacterium, Pseudomonas aeruginosa, is being experimented on in this model. 

News Archive

Prof Heidi Hudson appointed to international Committee on the Status of Women
2015-11-24

Prof Heidi Hudson is looking forward to advancing women scholars globally
Photo: Supplied

Prof Heidi Hudson, director of the Centre for Africa Studies at the University of the Free State, was recently appointed by the President of the International Studies Association (ISA) to serve on the Committee on the Status of Women from March 2016 to April 2018. 

Representing over 100 countries, ISA has more than 6 500 members in North America and internationally, and is the most respected and widely-known scholarly association in the field of International Studies. 

She anticipates that her role on the committee will complement her research interests in feminist security theory and practice in Africa. “I am looking forward to playing a part in the advancement of southern scholars, and the promotion of their voice in global academe.”   

Prior to Professor Hudson’s appointment, she served as a member of the executive of the Feminist Theory and Gender Studies (FTGS) Section of ISA.

Representing women of the world in academia

The Committee on the Status of Women has the task of reviewing the status of women in the profession, and making recommendations to the president and the Governing Council of ISA on ways of tracking and increasing the status and visibility of women in the profession.

“Some of the goals of the committee for the 2014 to 2016 period include reaching out to women scholars in the global south; creating an ISA networking website for women scholars; and surveying perceptions of the international relations climate and its needs,” said Prof Hudson. It is also responsible for “tracking gender balance within ISA and its journals, and supporting ISA regions in fulfilling the mission of the Committee on the Status of Women,” she added.

Connecting scholars globally since 1959

The ISA has been the premier organisation for connecting scholars and practitioners in fields of international studies, and promoting research and education. ISA cooperates with 57 international studies organisations in more than 30 countries, is a member of the International Social Science Council, and enjoys non-governmental consultative status at the United Nations.

Prof Hudson’s research interests concentrate on discursive and material gender deficits of liberal peacebuilding in the post colony, amongst other subjects. She is also co-editor of International Feminist Journal of Politics.

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept